Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group.

PURPOSE Follicular lymphoma is an indolent lymphoma with a long median overall survival. However, a considerable number of patients die within the first 2 years after the onset of the disease. Because the treatment options vary with respect to antitumor effect and potential toxic adverse effects, the identification of high-risk patients would be helpful in directing therapeutic decisions in individual patients. Several histopathologic biomarkers for risk stratification have been suggested, but most markers have not been validated in patients treated in prospective trials. PATIENTS AND METHODS We report a comprehensive approach to evaluate histopathologic biomarkers, including WHO grade, histology, and proliferation and quantitation of immune bystander cells, in 158 patients with nodal advanced-stage follicular lymphoma treated first line within a randomized trial. RESULTS Tumor sclerosis was a significant prognostic marker of poor overall survival that was independent of the Follicular Lymphoma International Prognostic Index (FLIPI). WHO grade, proliferation, and total T-cell or macrophage content were not associated with overall survival. CONCLUSION The presence of sclerosis within the lymphoma is a marker of poor overall survival that is independent of the FLIPI. The quantification of macrophage or absolute T-cell content, grading, and proliferation are of no help in predicting the outcome of FL. Future studies need to identify surrogate markers for the prognostic immune signatures identified by gene expression profiling. Most importantly, new prognostic markers need to be confirmed in patients treated within prospective trials.

[1]  Philip M Kluin,et al.  Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  B. Sander,et al.  CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma , 2007, Clinical Cancer Research.

[3]  W. Hiddemann,et al.  Clinical Trials and Observations , 2005 .

[4]  Marylène Lejeune,et al.  Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Calaminici,et al.  Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Emili Montserrat,et al.  High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. , 2006, Blood.

[7]  E. Giné,et al.  The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  E. Hoster,et al.  Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas , 2006, Cancer.

[9]  E. Hoster,et al.  The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect , 2006, Blood.

[10]  Richard Simon,et al.  Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.

[11]  R. Spang,et al.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.

[12]  P. Solal-Céligny.  Follicular Lymphoma International Prognostic Index. , 2004, Current treatment options in oncology.

[13]  G. Brittinger,et al.  Repp86: a new prognostic marker in mantle cell lymphoma , 2005, European journal of haematology.

[14]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[15]  N. Harris,et al.  Low Histologic Grade Follicular Lymphoma With High Proliferation Index: Morphologic and Clinical Features , 2005, The American journal of surgical pathology.

[16]  Karey Shumansky,et al.  Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). , 2005, Blood.

[17]  Christian Buske,et al.  Treatment strategies in follicular lymphomas: current status and future perspectives. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Kuriakose,et al.  Hematologic malignancies with primary retroperitoneal presentation: clinicopathologic study of 32 cases. , 2005, Archives of pathology & laboratory medicine.

[19]  Peter Joosten,et al.  Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. , 2005, Blood.

[20]  Prof. Dr. med. Alfred Christian Feller,et al.  Histopathology of Nodal and Extranodal Non-Hodgkin’s Lymphomas , 2012, Springer Berlin Heidelberg.

[21]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[22]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[23]  Adrian Wiestner,et al.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. , 2003, Blood.

[24]  H. Döhner,et al.  Cytogenetic evolution of follicular lymphoma. , 2003, Seminars in cancer biology.

[25]  F. Berthold,et al.  Repp86 expression and outcome in patients with neuroblastoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Gascoyne,et al.  Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes , 2003, British journal of haematology.

[27]  L. Staudt,et al.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.

[28]  R. Siebert,et al.  Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[30]  S. Horning,et al.  Follicular lymphoma: have we made any progress? , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  B. Nathwani,et al.  Clinical significance of follicular lymphoma with monocytoid B cells. Non-Hodgkin's Lymphoma Classification Project. , 1999, Human pathology.

[32]  M. Fernö,et al.  Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. , 1999, Journal of the National Cancer Institute.

[33]  M. Du,et al.  Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone. , 1998, Blood.

[34]  R. Parwaresch,et al.  The immunohistochemical marker Ki-S2: cell cycle kinetics and tissue distribution of a novel proliferation-specific antigen. , 1998, Modern Pathology.

[35]  James Olen Armitage,et al.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.

[36]  W. Chan,et al.  Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. , 1995, Blood.

[37]  S. Horning.  Natural history of and therapy for the indolent non-Hodgkin's lymphomas. , 1993, Seminars in oncology.

[38]  Prof. Dr. Dr. h.c. mult. Karl Lennert,et al.  Histopathology of Non-Hodgkin’s Lymphomas , 1992, Springer Berlin Heidelberg.

[39]  O. Kucuk,et al.  Effect of the degree of nodularity on the survival of patients with nodular lymphomas. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  S. Horning,et al.  Follicular and diffuse mixed small-cleaved and large-cell lymphoma--a clinicopathologic study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  G. Brittinger,et al.  Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group , 1984, Hematological oncology.

[42]  E. Jaffe,et al.  Prolonged initial remission in patients with nodular mixed lymphoma. , 1984, Annals of internal medicine.

[43]  R. Warnke,et al.  The coexistence of nodular and diffuse patterns in nodular non‐Hodgkin's lymphomas. Significance and clinicopathologic correlation , 1977, Cancer.